{"schema_version":"secwatch.filing_event.v1","accession":"0001933414-25-000139","form_type":"8-K","ticker":"MLYS","cik":"0001933414","company_name":"Mineralys Therapeutics, Inc.","filed_at":"2025-11-10T23:59:59+00:00","discovered_at":"2026-05-14T18:02:41.091089+00:00","generated_at":"2026-05-16T22:40:56.614576+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Mineralys Therapeutics Q3 net loss $36.9M; NDA planned late-2025/Q1 2026; cash $593.6M","bullets":["Net loss $36.9M for Q3 2025 vs $56.3M YoY; R&D expenses fell to $31.5M from $54.0M.","Cash, cash equivalents and investments $593.6M at Sep 30, 2025 (Dec 31, 2024: $198.2M) after $287.5M equity financing.","NDA submission for lorundrostat planned late 2025 or Q1 2026 following pre-NDA FDA feedback.","Enrollment complete in Explore-OSA Phase 2 trial; topline data anticipated Q1 2026.","Company expects current cash to fund planned clinical and regulatory activities into 2028."],"urls":{"canonical":"https://secwatch.observer/filing/0001933414-25-000139","json":"https://secwatch.observer/filing/0001933414-25-000139.json","markdown":"https://secwatch.observer/filing/0001933414-25-000139.md","text":"https://secwatch.observer/filing/0001933414-25-000139.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1933414/000193341425000139/0001933414-25-000139-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1933414/000193341425000139/mlys-20251110.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T22:40:56.614576+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}